Publications by authors named "David Beno"

Claim this Profile
H
Highlights of the Structure-Activity Relationships of Benzimidazole Linked Pyrrolidines Leading to the Discovery of the Hepatitis C Virus NS5A Inhibitor Pibrentasvir (ABT-530).
Rolf Wagner, John T Randolph, Sachin V Patel, Lissa Nelson, Mark A Matulenko, David A Beno

J Med Chem· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and Biological Characterization of Aryl Uracil Inhibitors of Hepatitis C Virus NS5B Polymerase: Discovery of ABT-072, a trans-Stilbene Analog with Good Oral Bioavailability.
John T Randolph, A Chris Krueger, Pamela L Donner, John K Pratt, Dachun Liu, David W A Beno

J Med Chem· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of fluorobenzimidazole HCV NS5A inhibitors.
John T Randolph, Charles A Flentge, Pamela Donner, Todd W Rockway, Sachin V Patel, David W A Beno

Bioorg Med Chem Lett· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A (14)C-leucine absorption, distribution, metabolism and excretion (ADME) study in adult Sprague-Dawley rat reveals β-hydroxy-β-methylbutyrate as a metabolite.
Anthony J Lee, David W A Beno, Xiaolin Zhang, Robin Shapiro, Mark Mason

Amino Acids· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
David A DeGoey, John T Randolph, Dachun Liu, John Pratt, Charles Hutchins, David W A Beno

J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High potency improvements to weak aryl uracil HCV polymerase inhibitor leads.
Pamela Donner, John T Randolph, Peggy Huang, Rolf Wagner, Clarence Maring, David Beno

Bioorg Med Chem Lett· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Aryl uracil inhibitors of hepatitis C virus NS5B polymerase: synthesis and characterization of analogs with a fused 5,6-bicyclic ring motif.
A Chris Krueger, John T Randolph, David A DeGoey, Pamela L Donner, Charles A Flentge, David W A Beno

Bioorg Med Chem Lett· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Novel hepatitis C virus replicon inhibitors: synthesis and structure-activity relationships of fused pyrimidine derivatives.
A Chris Krueger, Darold L Madigan, David W Beno, David A Betebenner, Robert Carrick

Bioorg Med Chem Lett· March 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification and preliminary characterization of a potent, safe, and orally efficacious inhibitor of acyl-CoA:diacylglycerol acyltransferase 1.
Vince S C Yeh, David W A Beno, Sevan Brodjian, Michael E Brune, Steven C Cullen

J Med Chem· February 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C NS5B polymerase inhibitors: functional equivalents for the benzothiadiazine moiety.
Douglas K Hutchinson, Charles A Flentge, Pamela L Donner, Rolf Wagner, Clarence J Maring, David W A Beno

Bioorg Med Chem Lett· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Synthesis and biological characterization of B-ring amino analogues of potent benzothiadiazine hepatitis C virus polymerase inhibitors.
John T Randolph, Charles A Flentge, Peggy P Huang, Douglas K Hutchinson, Larry L Klein, David W A Beno

J Med Chem· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibitors of hepatitis C virus polymerase: synthesis and biological characterization of unsymmetrical dialkyl-hydroxynaphthalenoyl-benzothiadiazines.
Rolf Wagner, Daniel P Larson, David W A Beno, Todd D Bosse, John F Darbyshire

J Med Chem· March 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hepatitis C NS5B polymerase inhibitors: 4,4-Dialkyl-1-hydroxy-3-oxo-3,4-dihydronaphthalene-3-yl benzothiadiazine derivatives.
Douglas K Hutchinson, Teresa Rosenberg, Larry L Klein, Todd D Bosse, Daniel P Larson, David W A Beno

Bioorg Med Chem Lett· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of diacyl glycerolacyltransferase I as a novel target for the treatment of obesity and dyslipidemia using a potent and selective small molecule inhibitor.
Gang Zhao, Andrew J Souers, Martin Voorbach, H Doug Falls, Brian Droz, David W A Beno

J Med Chem· February 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity of a potent hepatitis C virus polymerase inhibitor in the chimpanzee model.
Chih-Ming Chen, Yupeng He, Liangjun Lu, Hock Ben Lim, Rakesh L Tripathi, David W A Beno

Antimicrob Agents Chemother· December 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of potent, selective, orally bioavailable stearoyl-CoA desaturase 1 inhibitors.
Gang Liu, John K Lynch, Jennifer Freeman, Bo Liu, Zhili Xin, David W A Beno

J Med Chem· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyrrolidine-constrained phenethylamines: The design of potent, selective, and pharmacologically efficacious dipeptidyl peptidase IV (DPP4) inhibitors from a lead-like screening hit.
Bradley J Backes, Kenton Longenecker, Gregory L Hamilton, Kent Stewart, Chunqiu Lai, David W A Beno

Bioorg Med Chem Lett· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and structure-activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitors.
Zhonghua Pei, Xiaofeng Li, Thomas W von Geldern, Kenton Longenecker, Daisy Pireh, David W A Beno

J Med Chem· April 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
N-{3-[2-(4-alkoxyphenoxy)thiazol-5-yl]-1-methylprop-2-ynyl}carboxy derivatives as acetyl-coA carboxylase inhibitors--improvement of cardiovascular and neurological liabilities via structural modifications.
Yu Gui Gu, Moshe Weitzberg, Richard F Clark, Xiangdong Xu, Qun Li, David W A Beno

J Med Chem· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of adamantane ethers as inhibitors of 11beta-HSD-1: Synthesis and biological evaluation.
Jyoti R Patel, Qi Shuai, Jurgen Dinges, Marty Winn, Marina Pliushchev, David W A Beno

Bioorg Med Chem Lett· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Constrained 7-fluorocarboxychromone-4-aminopiperidine based Melanin-concentrating hormone receptor 1 antagonists: the effects of chirality on substituted indan-1-ylamines.
Andrew J Souers, Rajesh R Iyengar, Andrew S Judd, David W A Beno, Ju Gao

Bioorg Med Chem Lett· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Hemodynamic effects of potent and selective JNK inhibitors in anesthetized rats: implication for targeting protein kinases in metabolic diseases.
Gang Liu, Hongyu Zhao, Bo Liu, Zhili Xin, Mei Liu, David W A Beno

Bioorg Med Chem Lett· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Jeffrey J Rohde, Marina A Pliushchev, Bryan K Sorensen, Dariusz Wodka, Qi Shuai, David W A Beno

J Med Chem· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of ((4R,5S)-5-amino-4-(2,4,5- trifluorophenyl)cyclohex-1-enyl)-(3- (trifluoromethyl)-5,6-dihydro- [1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone (ABT-341), a highly potent, selective, orally efficacious, and safe dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes.
Zhonghua Pei, Xiaofeng Li, Thomas W von Geldern, David J Madar, Kenton Longenecker, David W A Beno

J Med Chem· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of 2-[4-{{2-(2S,5R)-2-cyano-5-ethynyl-1-pyrrolidinyl]-2-oxoethyl]amino]- 4-methyl-1-piperidinyl]-4-pyridinecarboxylic acid (ABT-279): a very potent, selective, effective, and well-tolerated inhibitor of dipeptidyl peptidase-IV, useful for the treatment of diabetes.
David J Madar, Hana Kopecka, Daisy Pireh, Hong Yong, Zhonghua Pei, David W A Beno

J Med Chem· October 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis